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Due to blood transfusions, pregnancy, and organ/tissue
transplants or grafts,1 red blood cell alloimmunization may
lead to serious complications, such as hemolytic transfusion
reactions,2–4 which have been regarded as one of the most
frequent causes of transfusion-related deaths in recent years
according to reports from the Food and Drug Administration
(FDA).5
Rh, the most complex blood group system, has the highest
clinical importance after the ABO group.6,7 The D antigen,
found in Rh-positive individuals, is the most important in the
system as it is the most immunogenic.7,8 Therefore, given the
risk of alloimmunization, RhD-positive red blood cells must
not be transfused to RhD-negative patients except in emer-
gencies involving massive hemorrhage when RhD-negative
units are not available.7
The RhD protein has 417 amino acids divided into seven
intracellular segments, twelve transmembrane segments and
six extracellular segments.9 Amino acid substitution in the
intracellular or transmembrane segment of the RhD protein
leads to weakening of the D antigen expression in the mem-
brane of red blood cells resulting in a weak D phenotype.6–13
Hence, weak D testing must always be performed in blood
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reserved.donors with absent reactivity in the screening test, and if the
results are weakly positive, the donors must be classiﬁed as
RhD-positive in order to prevent anti-D alloimmunization in
RhD-negative patients who receive transfusions of packed red
blood cells.6–8,10
From the 1980s, the introduction of monoclonal anti-D
reagents in the United States have helped to increase weak
D antigen detection by using serological methods. In routine
laboratory investigations, blood samples are found to have this
phenotype when the reactivity of red blood cells with anti-D
serum is absent or weakly positive (≤2+) in the screening test,
yet with moderate or strong agglutination when antiglobulin
serum is added,10 or when RhD genotyping is demonstrated
by molecular methods.
Nonetheless, in some cases, standard serological methods
may not detect red blood cells with the weakly expressed D
antigen and thus, RhD-positive donors are erroneously typed
as RhD negative,11,13 despite the improvement in the sen-
sitivity of detection that has been observed using different(UFTM), Av. Getúlio Guaritá, 250, Abadia, 38025-440 Uberaba, MG,
monoclonal antibody reagents.
A study by Schmidt et al.14 showed positive results for the
RhD antigen in 5.9% of 152 blood donors – who  had been
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reviously identiﬁed as RhD negative in routine examina-
ions – when using anti-D IgG monoclonal antibodies (clones
SD1, MS-26 and TH-28) in gel cards. In the same study, the
uthors evaluated another population of 4897 donors from dif-
erent regions of Minas Gerais state, Brazil, who had all been
reviously phenotyped as D negative in the indirect antiglob-
lin test (IAT), with clones MS-26 and TH-28, and 70 (1.43%)
ndividuals showed weak reactivity with ESD1 anti-D anti-
odies. Molecular analysis were performed for 39 of these
0 individuals with RHD positivity conﬁrmed by a multiplex
HD genotyping assay, whereas other molecular techniques
uch as polymerase chain reaction-sequence-speciﬁc primers
PCR-SSP) and RHD BeadChip were effective in speciﬁcally
dentifying different RHD variants in 48.71% of these 39 RHD
ositive samples. However, it would be important that the
egative samples of ESD1 anti-D clone were also subjected to
olecular analysis so as to establish the level of sensitivity of
his antiserum.
Costa et al.15 found, by molecular methods, that 18 (3.4%)
f 520 donors previously classiﬁed as RhD negative in São
aulo, Brazil, carried different RHD variants. Moreover, the
uthors observed that four (22.2%) of these 18 individuals had
 negative IAT, even though 11 different monoclonal anti-D
ntibodies (including clone ESD1) were used, whereas the
ther individuals showed a weak or very poor reaction to ﬁve
f these antibodies, as well as negative reactions to six of
hese antisera.
It  is consensus that molecular techniques allowed the start
f a new stage of blood donor typing, including several strate-
ies to identify RhD variants that are potentially immunogenic
n apparently RhD-negative donors, as shown in several
tudies.11–17 Furthermore, in some of these studies, these vari-
nts were also found to be associated with the C and E antigens
f the Rh system,11,12,14,15 although some RhD subtypes were
ound in ccee individuals.13 Techniques have now identiﬁed
ore  than 200 variants of the D antigen, including weak D,
 partial and DEL types.16 Of this total, over 80 belong to the
eak D phenotype (11), with subtypes 1, 2 and 3 being the most
revalent.10 It is known that 0.2–1% of European and American
aucasian individuals are carriers of this phenotype.10
Advances in serological and molecular techniques have
ade the detection of the different variants of RhD increas-
ngly more  accurate in recent years. Donors who were once
yped as RhD negative have been reclassiﬁed as RhD positive,
ence increasing transfusion safety for RhD-negative patients.
herefore, the adoption of improved serological methods and
n particular molecular techniques is key to the routine of
mmunohematology laboratories to standardize tests to iden-
ify weakly expressed D antigens and other RhD variants. This
rocedure allows the correct classiﬁcation of the RhD status
f blood donors, thus minimizing the risk of anti-D alloim-
unization and hemolytic reactions, as well as increasing
ransfusion safety of RhD-negative patients, including women
f childbearing age, receiving transfusions of packed red blood
ells. Therefore, hemolytic disease of the fetus and newborn
y antibodies directed against D antigen is prevented.onﬂicts  of  interest
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